Holen Sie sich die Stockscreener-App
17.46
0.06%
0.1801
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Summit Therapeutics stock surges on Jefferies upgrade to buy By Investing.com - Investing.com Canada
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com UK
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 61.45% Upside - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress - Yahoo Finance
Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits
Why Is SMMT Stock Tumbling Today? - Stocktwits
Ivonescimab Demonstrates an Overall Survival Benefit in Advanced NSCLCSummit Therapeutics - Oncodaily
Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival DataAnd What's Next - simplywall.st
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S. (SMMT) - Seeking Alpha
Why is Summit Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Summit's Ivonescimab Beats Merck's Keytruda on Survival in Chinese Lung Cancer Trial - finance.biggo.com
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug - Barron's
Why Is Summit Therapeutics Stock Soaring Today?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - Benzinga
Why is Summit Therapeutics stock surging today? - Investing.com
Summit Therapeutics stock rises on positive survival data By Investing.com - Investing.com Nigeria
Ivonescimab shows statistically significant OS vs pembrolizumab in HARMONi-2, Summit Therapeutics notes - TradingView
Summit Therapeutics stock rises on positive survival data - Investing.com
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet - Seeking Alpha
Summit Therapeutics (SMMT) Gains on Positive Phase III Trial Res - GuruFocus
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China - Yahoo Finance
Cantor Fitzgerald reiterates Summit Therapeutics stock rating - Investing.com
Weekly Recap: HARMONi Phase III PFS improvement and Bernstein upgrade - TradingView
Summit Therapeutics Inc. (SMMT) Stock Analysis: Assessing a Potential 107.71% Upside in Biotech - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Stock Climbed, So What Is Behind The Move? - Yahoo Finance
Summit Therapeutics (SMMT) Is Up 8.5% After New Phase III Biliary Cancer Data For Ivonescimab - Yahoo Finance
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Movi - Benzinga
Summit Therapeutics stock jumps on partner’s cancer trial data - Investing.com
Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints - marketscreener.com
Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients - Sahm
Summit Therapeutics Inc. (SMMT): Growth Potential and Analyst Consensus with 117.45% Upside - DirectorsTalk Interviews
Summit Therapeutics (NASDAQ:SMMT) Trading Up 7.2%Still a Buy? - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Given "Neutral" Rating at HC Wainwright - MarketBeat
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year LowHere's Why - MarketBeat
Summit Therapeutics (SMMT) Shares Drop 8.5% Amid Valuation Conce - GuruFocus
Summit Therapeutics Inc. (SMMT) Stock Analysis: A 114% Potential Upside Amid Biotech Innovations - DirectorsTalk Interviews
Summit Therapeutics (NASDAQ:SMMT): What Could Drive Its Next Move? - Kalkine Media
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7%Here's Why - MarketBeat
Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
SMMT - Finviz
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Singapore
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $28.34, Implies 88% Upside - TradingView
Summit Therapeutics (SMMT) Stock Gains on China Label Expansion for Ivonescimab - GuruFocus
Summit lead drug granted China label expansion (SMMT:NASDAQ) - Seeking Alpha
Can Summit Therapeutics (NASDAQ:SMMT) Extend Its Momentum? - Kalkine Media
Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC - marketscreener.com
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners - MarketBeat
Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 - marketscreener.com
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a 103% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative? - Sahm
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics - GlobeNewswire
Ivonescimab Expands Into First-Line Bladder Cancer – Summit Therapeutics - Oncodaily
Summit Therapeutics (SMMT) Launches Global Phase II/III Trial fo - GuruFocus
Summit TherapeuticsInitiates Global Phase Ii/Iii Harmoni-Gu1 Trial Of Ivonescimab In Bladder Cancer - TradingView
Summit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study - Stock Titan
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business Wire
Jim Cramer Stock Picks: Summit Therapeutics Is A 'Great Spec'Carvana (NYSE:CVNA) - benzinga.com
The Manufacturers Life Insurance Company Has $11.24 Million Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Clear Street Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 117.69% Upside - DirectorsTalk Interviews
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Summit Therapeutics upgraded to Hold as FDA rev... - Pluang
Summit Therapeutics (SMMT) Is Down 13.2% After Equity Offering And Ivonescimab Updates Has The Bull Case Changed? - Sahm
Summit Therapeutics Reports Q2 2026 Financial Results and Major Clinical Progress for Ivonescimab - Oncodaily
Summit Therapeutics stock hits 52-week low at 12.52 USD By Investing.com - Investing.com Canada
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):